New combo aims to beat hepatitis b by waking up immune cells

NCT ID NCT05769816

First seen Sep 30, 2025 · Last updated Apr 24, 2026 · Updated 25 times

Summary

This study tests a new combination treatment for chronic hepatitis B that aims to achieve a functional cure, meaning the virus is controlled without lifelong medication. About 120 adults with hepatitis B will receive an immune-boosting drug (anti-PD-1 antibody) along with standard antivirals. The goal is to see if this approach can clear the hepatitis B surface antigen (HBsAg) in more than 50% of patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The 2nd affiliated Hospital of Chongqing Medical University

    RECRUITING

    Chongqing, Chongqing Municipality, 400010, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.